Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-VV500 With or Without Rapamycin in Relapsed or Refractory Multiple Myeloma
NCT07735546Phase 1Not yet recruiting
- Sponsor
- Umoja Biopharma
- Start
- Oct 2026
- Primary completion
- Dec 2029
01
Overview
Phase 1, open-label trial of UB-VV500 in multiple myeloma (MM) (2 arms), sponsored by Umoja Biopharma. Primary endpoint: Adverse Events at 2 years. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
UB-VV500
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07735546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07735546.